CTLT stock forecast
Our latest prediction for Catalent, Inc.'s stock price was made on the Dec. 12, 2017 when the stock price was at 39.54$.
In the short term (2weeks), CTLT's stock price should underperform the market by -0.04%. During that period the price should oscillate between -4.88% and +4.66%.
In the medium term (3months), CTLT's stock price should underperform the market by -0.36%. During that period the price should oscillate between -11.95% and +12.88%.Get email alerts
About Catalent, Inc.
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. It operates through the following segments: Softgel Technologies; Biologics and Specialty Drug Delivery; Oral Drug Delivery; and Clinical Supply Services. The Softgel Technologies segment formulate, develop, and manufacture services for soft capsules. The Biologics and Specialty Drug Delivery segment develops and manufacture services for blow-fill-seal unit doses, prefilled syringes, vials, and cartridges; analytical development and testing services for large molecules; inhaled products for delivery via metered dose inhalers, dry powder inhalers, and intra-nasal sprays. The Oral Drug Delivery segment focuses in the formulation development and manufacturing technologies, and related solutions including: clinical development and commercial manufacturing of a range of oral dose forms, including proprietary fast-dissolve Zydis tablets and both conventional immediate and controlled release tablets, capsules, and sachet products. The Clinical Supply Services segment includes packaging, labeling, storage, distribution, and inventory management for drugs and biologics in clinical trials. The company was founded in April 2007 and is headquartered in Somerset, NJ.
At the moment the company generates 2631M USD in revenues.
On its last earning announcement, the company reported a profit of 0.95$ per share.
The book value per share is 7.50$
Three months stock forecastDec. 12, 2017
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|